» Articles » PMID: 30056763

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells

Overview
Journal Cell Transplant
Date 2018 Jul 31
PMID 30056763
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) represent a promising cell source for patient-specific cell therapy. We previously demonstrated that they display an immunomodulatory effect on allergic airway inflammation. Glucocorticoids are powerful anti-inflammatory compounds and widely used in the therapy of allergic diseases. However, the effect of glucocorticoids on the immunomodulatory function of iPSC-MSCs remains unknown. This study aimed to determine the effect of dexamethasone (Dex) on the immunomodulatory function of iPSC-MSCs in vitro and in vivo. A total of three human iPSC-MSC clones were generated from amniocyte-derived iPSCs. Anti-CD3/CD28-induced peripheral blood mononuclear cell (PBMC) proliferation was used to assess the effect of Dex on the immunoinhibitory function of iPSC-MSCs in vitro. Mouse models of contact hypersensitivity (CHS) and allergic airway inflammation were induced, and the levels of inflammation in mice were analyzed with the treatments of iPSC-MSCs and Dex, alone and combined. The results showed that Dex did not interfere with the immunoinhibitory effect of iPSC-MSCs on PBMC proliferation. In CHS mice, simultaneous treatment with Dex did not affect the effect of iPSC-MSCs on the inflammation, both in regional draining lymph nodes and in inflamed ear tissue. In addition, co-administration of iPSC-MSCs with Dex decreased the local expression of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the ears of CHS mice. In the mouse model of allergic airway inflammation, iPSC-MSC treatment combined with Dex resulted in a similar extent of reduction in pulmonary inflammation as iPSC-MSCs or Dex treatment alone. In conclusion, Dex does not significantly affect the immunomodulatory function of iPSC-MSCs both in vitro and in vivo. These findings may have implications when iPSC-MSCs and glucocorticoids are co-administered.

Citing Articles

Targeting miR-223 enhances myeloid-derived suppressor cell suppressive activities in multiple sclerosis patients.

Cantoni C, Ghezzi L, Choi J, Cross A, Piccio L Mult Scler Relat Disord. 2023; 76:104839.

PMID: 37364375 PMC: 10957070. DOI: 10.1016/j.msard.2023.104839.


Mesenchymal Stem Cells and Their Exocytotic Vesicles.

Cai H, Guo H Int J Mol Sci. 2023; 24(3).

PMID: 36768406 PMC: 9916886. DOI: 10.3390/ijms24032085.


Development of a physiomimetic model of acute respiratory distress syndrome by using ECM hydrogels and organ-on-a-chip devices.

Marhuenda E, Villarino A, Narciso M, Elowsson L, Almendros I, Westergren-Thorsson G Front Pharmacol. 2022; 13:945134.

PMID: 36188621 PMC: 9517737. DOI: 10.3389/fphar.2022.945134.


Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells.

Dupuis V, Oltra E World J Stem Cells. 2021; 13(8):1094-1111.

PMID: 34567428 PMC: 8422924. DOI: 10.4252/wjsc.v13.i8.1094.


Pluripotent-derived Mesenchymal Stem/stromal Cells: an Overview of the Derivation Protocol Efficacies and the Differences Among the Derived Cells.

de Matos B, Robert A, Stimamiglio M, Correa A Stem Cell Rev Rep. 2021; 18(1):94-125.

PMID: 34545529 DOI: 10.1007/s12015-021-10258-z.


References
1.
Uccelli A, Pistoia V, Moretta L . Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol. 2007; 28(5):219-26. DOI: 10.1016/j.it.2007.03.001. View

2.
Yamanaka S . Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2008; 1(1):39-49. DOI: 10.1016/j.stem.2007.05.012. View

3.
Wu K, Chan C, Tsai C, Chang Y, Sieber M, Chiu T . Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation. 2011; 91(12):1412-6. DOI: 10.1097/TP.0b013e31821aba18. View

4.
Faiella W, Atoui R . Immunotolerant Properties of Mesenchymal Stem Cells: Updated Review. Stem Cells Int. 2016; 2016:1859567. PMC: 4709780. DOI: 10.1155/2016/1859567. View

5.
Lian Q, Zhang Y, Zhang J, Zhang H, Wu X, Zhang Y . Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010; 121(9):1113-23. DOI: 10.1161/CIRCULATIONAHA.109.898312. View